Inozyme Pharma, Inc. Powers Up – Prices Public Offering of Common Stock

Inozyme Pharma, Inc., the clinical-stage biopharmaceutical company, has announced a public offering of 12.5 million shares of its common stock at a price of $4.80 per share to raise approximately $60 million in gross proceeds.

Additionally, the underwriters have been granted an option to purchase up to an additional 1.875 million shares of common stock at the public offering price for a period of 30 days. These funds will support Inozyme’s innovative therapeutics for the treatment of pathologic mineralization and intimal proliferation.

BofA Securities, TD Cowen, and Piper Sandler are delighted to announce that they are acting as joint book-running managers for an offering that is expected to close on or about August 1, 2023, subject to satisfaction of customary closing conditions. Wedbush PacGrow and Needham & Company will also join in and act as co-managers for the offering. Don’t miss this opportunity to be a part of this exciting undertaking!

About Inozyme Pharma, Inc.

Inozyme Pharma, Inc. is revolutionizing the treatment of rare diseases impacting the vasculature, soft tissue and skeleton. Through their enzyme replacement therapy, INZ-701, they are striving to address one of the most debilitating complications of these diseases – pathologic mineralization and intimal proliferation. Clinical trials for INZ-701 are already underway to treat ENPP1 Deficiency and ABCC6 Deficiency, giving hope to those suffering from these diseases.

Leave a Comment